Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial

International Journal of Hematology

Volumn 105, Issue 2, 2017, Pages 206-212

  Mori, Takehiko ^a   Kanda, Yoshinobu ^b   Takenaka, Katsuto ^c   Okamoto, Shinichiro ^a   Kato, Jun ^a   Kanda, Junya ^b   Yoshimoto, Goichi ^c   Gondo, Hisashi ^d   Doi, Sayaka ^e   Inaba, Masaki ^e   Kodera, Yoshihisa ^f  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d Saga Ken Medical Centre Koseikan   (Japan)

^e ASTELLAS PHARMA INC   (Japan)

^f AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ASP0113; Cytomegalovirus; DNA vaccine; Hematopoietic cell transplantation; Phase 2 open label trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; VIRUS ANTIGEN;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; HYPERURICEMIA; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; JAPANESE (PEOPLE); MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; THROMBOCYTE COUNT; VACCINATION; VIRUS LOAD; ADVERSE EFFECTS; ALLOGRAFT; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; ALLOGRAFTS; ANTIGENS, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84992702656     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-2110-3     Document Type: Article

References (24)

1. Furui Y, Satake M, Hoshi Y, Uchida S, Suzuki K, Tadokoro K. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion. 2013;53:2190–7.
2. Ishibashi K, Tokumoto T, Shirakawa H, Hashimoto K, Kushida N, Yanagida T, et al. Strain-specific seroepidemiology and reinfection of cytomegalovirus. Microbes Infect. 2008;10:1363–9.
3. Shigemi D, Yamaguchi S, Otsuka T, Kamoi S, Takeshita T. Seroprevalence of cytomegalovirus IgG antibodies among pregnant women in Japan from 2009–2014. Am J Infect Control. 2015;43:1218–21.
4. Taniguchi K, Watanabe N, Sato A, Jwa SC, Suzuki T, Yamanobe Y, et al. Changes in cytomegalovirus seroprevalence in pregnant Japanese women-a 10-year single center study. J Clin Virol. 2014;59:192–4.
5. Nishihori T, Shaheen M, El-Asmar J, Aljurf M, Kharfan-Dabaja MA. Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. Immunotherapy. 2015;7:1059–71.
6. Razonable RR, Eid AJ. Viral infections in transplant recipients. Minerva Med. 2009;100:479–501.
7. Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, Rubin RH, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematol Am Soc Hematol Educ Program. 2001;392–421.
8. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematol Am Soc Hematol Educ Program. 2011;2011:305–9.
9. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25:151–69.
10. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003–8.
11. Ahmed A. Antiviral treatment of cytomegalovirus infection. Infect Disord Drug Targets. 2011;11:475–503.
12. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antivir Res. 2006;71:154–63.
13. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–14.
14. Selinsky C, Luke C, Wloch M, Geall A, Hermanson G, Kaslow D, et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin. 2005;1:16–23.
15. Schleiss MR. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther. 2009;11:572–8.
16. + T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–85.
17. Cranage MP, Kouzarides T, Bankier AT, Satchwell S, Weston K, Tomlinson P, et al. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J. 1986;5:3057–63.
18. Kharfan-Dabaja MA, Nishihori T. Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. Expert Rev Vaccines. 2015;14:341–50.
19. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:290–9.
20. Wloch MK, Smith LR, Boutsaboualoy S, Reyes L, Han C, Kehler J, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis. 2008;197:1634–42.
21. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.
22. Pergam SA, Xie H, Sandhu R, Pollack M, Smith J, Stevens-Ayers T, et al. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant. 2012;18:1391–400.
23. Becker BN, Schulman G. Nephrotoxicity of antiviral therapies. Curr Opin Nephrol Hypertens. 1996;5:375–9.
24. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48:199–226.